Ryan Livingston

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

A recent study highlights the efficacy of the FAi implant in patients with NIU-related macular edema, improving BCVA and reducing choroidal thickness.

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors.

EYE PCR’s fixOflex is now eligible for European market introduction, providing clinicians with a method of preserving the capsular bag’s form after cataract surgery.